Home/Pipeline/MSC Therapy for AD

MSC Therapy for AD

Alzheimer's Disease

Phase 1Active

Key Facts

Indication

Alzheimer's Disease

Phase

Phase 1

Status

Active

Company

StromaBio

About StromaBio

StromaBio is a Swedish clinical-stage biotech leveraging over two decades of foundational research to develop allogeneic mesenchymal stromal cell (MSC) therapies. Its platform targets high-need areas in inflammatory and neurodegenerative diseases, specifically ARDS and Alzheimer's Disease. The company is built on a strong IP position and a decade of pre-clinical and clinical data, positioning it to advance two product candidates toward market authorization.

View full company profile

Therapeutic Areas

Acute Respiratory Distress Syndrome Alzheimer's Disease

Other Alzheimer's Disease Drugs

Drug	Company	Phase	Status
NUZ-001	Neurizon Therapeutics	Preclinical	Active
ALZN002	Alzamend Neuro	Preclinical	Research
P021	Phanes Biotech	Preclinical	Active
PB43D	Phanes Biotech	Preclinical	Active
UB-311	Vaxxinity	Phase 2	Active
Lecanemab	BioArctic	Launched	Active (Commercial)
BAN2401	BioArctic	Preclinical	Active
Undisclosed Programs	johnson-and-johnson-innovative-medicine	Pipeline	Active
MK-6240 (florquinitau)	Lantheus Medical Imaging	Regulatory Filing	Filed
NAV-4694 (flutafuranol)	Lantheus Medical Imaging	Phase 3	Active
LNTH-2620/PI-2620	Lantheus Medical Imaging	Phase 3	Recruiting
itMSCs	Stemedica Cell Technologies	Clinical Development	Active